Tron Inc., the largest publicly traded holder of TRON (TRX) tokens, has been elected as one of the 27 Super Representative nodes on the TRON network, ranking #27 with 0.76 billion delegated TRX tokens as of October 18, 2026. This role allows Tron Inc. to participate in block production, transaction validation, network security, and governance, moving beyond just holding TRX tokens to actively supporting the blockchain's infrastructure. The company aims to generate recurring on-chain revenue and strengthen the TRON ecosystem, which is a leading platform for on-chain stablecoin payments and AI payment solutions. This move marks a strategic expansion in Tron Inc.'s blockchain involvement and commitment to delivering value to TRX holders and the broader community.
Tron Inc. election as a Super Representative on the TRON network offers context for readers. For those tracking US stocks on Pluang, 83 of 150 rose and 60 fell today. Notable gainers include INTC at USD 93.05 (+3.56%), UMC at USD 20.47 (+3.28%), and FCEL at USD 13.40 (+3.08%) as of Oct 19, 2026 18:32 WIB.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
